Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI

Description

This project's objective is to identify effective treatments for Gulf War Illness (GWI). The project tests three potential treatments: curcumin, stinging nettle, and resveratrol. The project uses a decentralized clinical trial (DCT) design in which individuals can participate from anywhere in the United States. Recruitment efforts will be designed to obtain a geographically and demographically diverse study sample.

Conditions

Gulf War Illness

Study Overview

Study Details

Study overview

This project's objective is to identify effective treatments for Gulf War Illness (GWI). The project tests three potential treatments: curcumin, stinging nettle, and resveratrol. The project uses a decentralized clinical trial (DCT) design in which individuals can participate from anywhere in the United States. Recruitment efforts will be designed to obtain a geographically and demographically diverse study sample.

Curcumin, Resveratrol, and Stinging Nettle as Treatments for Gulf War Illness

Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI

Condition
Gulf War Illness
Intervention / Treatment

-

Contacts and Locations

Birmingham

The University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Meets Kansas GWI Case Definition
  • * Meets CDC GWI Case Definition
  • * Able to commit to a 10-month study
  • * Currently involved in an experimental treatment study
  • * Abnormal liver function values
  • * Abnormal kidney function values
  • * Currently pregnant
  • * Blood clotting disorder (contraindicated with all three botanicals)
  • * Reported diagnosis of diabetes with an A1C greater than 9
  • * The use of contraindicated medications (see below):
  • * Anticoagulant medications (such as warfarin, heparin, etc.)
  • * Lithium
  • * Tacrolimus (Prograf)
  • * Cancer medications (Alkylating agents, antitumor antibiotics, Topoisomerase I inhibitors, Tamoxifen)

Ages Eligible for Study

45 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Alabama at Birmingham,

Jarred Younger, PhD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

2026-06-30